NTLA – intellia therapeutics, inc. (US:NASDAQ)
Stock Stats
News
11/22
08:42 am
ntla
Low
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? [Yahoo! Finance]
11/19
05:42 pm
ntla
Medium
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $90.00 price target on the stock.
11/18
01:35 pm
ntla
Low
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $70.00. They now have an "overweight" rating on the stock.
11/18
11:36 am
ntla
Low
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
11/18
11:34 am
ntla
Low
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
11/7/2024
07:30 am
ntla
-3.2%
BEAT
8/8/2024
07:30 am
ntla
6.6%
MISS
5/9/2024
07:30 am
ntla
3.6%
BEAT
2/22/2024
07:30 am
ntla
-0.4%
BEAT
11/19
05:25 pm
Maintains
Buy
Buy
Canaccord Genuity
Medium
-8.0%
11/18
01:25 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
1.0%
11/18
01:25 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
1.0%
11/18
11:36 am
Reiterates
Neutral
Neutral
Wedbush
Low
1.9%
11/18
11:36 am
Reiterates
Neutral
Neutral
Wedbush
Low
1.9%
11/18
07:01 am
ntla
High
Form 8-K Intellia Therapeutics, For: Nov 16
11/7
04:06 pm
ntla
Medium
Form 10-Q Intellia Therapeutics, For: Sep 30
11/7
07:45 am
ntla
Medium
Form 8-K Intellia Therapeutics, For: Nov 07
10/25
05:00 pm
ntla
Medium
Form 8-K Intellia Therapeutics, For: Oct 24
10/4
05:30 pm
ntla
Low
Form 4 Intellia Therapeutics, For: Oct 02 Filed by: Dube Michael P
Show more
Top News Gainers
2/27 Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call Transcript [The Motley Fool] 17.1%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
Top News Decliners
3/13 Form 8-K Intellia Therapeutics, For: Mar 12 -17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3